[go: up one dir, main page]

AR012694A1 - Preparado con compatibilidad in vivo incrementada y procedimiento para su produccion - Google Patents

Preparado con compatibilidad in vivo incrementada y procedimiento para su produccion

Info

Publication number
AR012694A1
AR012694A1 ARP980102233A ARP980102233A AR012694A1 AR 012694 A1 AR012694 A1 AR 012694A1 AR P980102233 A ARP980102233 A AR P980102233A AR P980102233 A ARP980102233 A AR P980102233A AR 012694 A1 AR012694 A1 AR 012694A1
Authority
AR
Argentina
Prior art keywords
compound
glycosyl
compatibility
atom
therapy
Prior art date
Application number
ARP980102233A
Other languages
English (en)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of AR012694A1 publication Critical patent/AR012694A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La terapia de tumores malignos, enfermedades infecciosas o enfermedades autoinmunes está ligada, junto a la insuficiente actividad de los agentesterapéuticos, con fuertes efectos secundarios. Esta carencia puede explicarse fundamentalmente con la compatiblidad in vivo demasiado escasa delos principios activos empleados. La invencion pretende, mediante la modificacion del preparado, mejorar la compatibilidad de principios activos enterapia y, eventualmente, incrementarla eficacia. Preparado con compatibilidad in vivo incrementada caracterizado porque contiene: 1) un compuesto de laformula (I), glicosil-Y[-C(=Y)-X-]p-W(R)n-X-C(=Y)- principio activo (I) en donde glicosil es un polisacárido, oligosacárido o monosacárido separablepor vía enzimática, W es un compuesto aromático o un compuesto heteroaromático o un compuesto alifático con dobles enlaces conjugados o un derivado deaminoácido ciclizante después de la separacion de resto glicosilo, y en dondeel sustituyente R es un átomo de hidrogeno, metilo, metoxi, carboxi, CN,metilcarbonilo, hidroxi, nitro, fluor, cloro, bromo, sulfonilo, sulfonamida o sulfon-alquil C1-4-amida, p es cero o 1, n es un numero entero, X es unátomo de oxígeno, NH, metilenoxi, metilenamino o metilen-alquil C1-4-amino, e Y es un átomo de oxígeno o NH, y principio activo significa un compuestocon actividad biologica enlazado a través de un grupo hidroxi, amino o imino, y/o un sal fisiologicamente compatible del compuesto de la formula (I), 2)azucar y/o azucar-alcohol y 3) un soporte farmacéuticamente compatible.
ARP980102233A 1997-05-15 1998-05-13 Preparado con compatibilidad in vivo incrementada y procedimiento para su produccion AR012694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19720312A DE19720312A1 (de) 1997-05-15 1997-05-15 Zubereitung mit erhöhter in vivo Verträglichkeit

Publications (1)

Publication Number Publication Date
AR012694A1 true AR012694A1 (es) 2000-11-08

Family

ID=7829495

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102233A AR012694A1 (es) 1997-05-15 1998-05-13 Preparado con compatibilidad in vivo incrementada y procedimiento para su produccion

Country Status (17)

Country Link
US (1) US6020315A (es)
EP (1) EP0879605B1 (es)
JP (1) JP4367798B2 (es)
KR (1) KR100547923B1 (es)
CN (1) CN1188134C (es)
AR (1) AR012694A1 (es)
AT (1) ATE333899T1 (es)
AU (1) AU740694B2 (es)
BR (1) BR9801632A (es)
CA (1) CA2237450A1 (es)
CZ (1) CZ149398A3 (es)
DE (2) DE19720312A1 (es)
HU (1) HUP9801087A3 (es)
ID (1) ID20283A (es)
PL (1) PL193478B1 (es)
RU (1) RU2234322C2 (es)
TR (1) TR199800848A3 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100405116B1 (ko) 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
DK0941227T5 (da) 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PT998272E (pt) * 1997-08-26 2003-09-30 Aventis Pharma Inc Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
KR100685336B1 (ko) 1999-02-22 2007-02-23 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) Ｃ-21 변형 에포틸론
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
NZ515134A (en) 1999-05-04 2004-01-30 Strakan Ltd Androgen glycosides and androgenic activity thereof
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB2355007A (en) * 1999-10-08 2001-04-11 Michael Francis Holick Tamoxifen analogue glycosides and use thereof
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
IL155291A0 (en) * 2000-10-16 2003-11-23 Neopharm Inc Liposomal formulation of mitoxantrone
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
BRPI0206509B8 (pt) 2001-01-25 2021-05-25 R Pharm Us Operating Llc processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
MXPA03006485A (es) 2001-01-25 2003-09-22 Bristol Myers Squibb Co Formulacion parenteral que contiene analogos de epotilona.
MXPA03007423A (es) 2001-02-20 2003-11-18 Bristol Myers Squibb Co Derivados de epotilona para tratamiento de tumores refractarios.
EP1385529A4 (en) 2001-02-20 2007-05-09 Bristol Myers Squibb Co TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES
IL157443A0 (en) 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
EP1392664A4 (en) 2001-06-01 2005-01-26 Bristol Myers Squibb Co EPOTHILONE DERIVATIVES
ATE371458T1 (de) * 2001-08-14 2007-09-15 Valderm Aps Behandlung von hyperproliferativen zuständen von körperoberflächen
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
PT1506203E (pt) 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN1705662B (zh) 2002-09-23 2011-07-06 布里斯托尔-迈尔斯斯奎布公司 埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
JP5180824B2 (ja) 2005-06-29 2013-04-10 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド ホスホルアミデートアルキル化剤プロドラッグ
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) * 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
EP2114157B1 (en) * 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US20090118031A1 (en) * 2007-11-01 2009-05-07 Qualizza Gregory K Shaft Structure with Configurable Bending Profile
WO2013026453A1 (en) * 2011-08-22 2013-02-28 Valderm Aps Treatment of inflammatory disorders with anthracyclines
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
EP0751144B1 (en) * 1995-06-27 2004-10-06 Pharmachemie B.V. Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy
ATE316799T1 (de) * 1996-03-12 2006-02-15 Sanofi Aventis Deutschland Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen

Also Published As

Publication number Publication date
HU9801087D0 (en) 1998-07-28
RU2234322C2 (ru) 2004-08-20
EP0879605A3 (de) 1998-12-02
DE59813653D1 (de) 2006-09-07
TR199800848A2 (xx) 1998-12-21
KR100547923B1 (ko) 2006-04-12
JP4367798B2 (ja) 2009-11-18
EP0879605B1 (de) 2006-07-26
PL326336A1 (en) 1998-11-23
EP0879605A2 (de) 1998-11-25
CA2237450A1 (en) 1998-11-15
ID20283A (id) 1998-11-19
CN1199613A (zh) 1998-11-25
AU6600598A (en) 1998-11-19
HUP9801087A3 (en) 1999-05-28
ATE333899T1 (de) 2006-08-15
US6020315A (en) 2000-02-01
TR199800848A3 (tr) 1998-12-21
BR9801632A (pt) 1999-06-29
CZ149398A3 (cs) 1998-12-16
JPH1129497A (ja) 1999-02-02
PL193478B1 (pl) 2007-02-28
AU740694B2 (en) 2001-11-15
CN1188134C (zh) 2005-02-09
DE19720312A1 (de) 1998-11-19
KR19980087239A (ko) 1998-12-05
HUP9801087A2 (hu) 1998-12-28

Similar Documents

Publication Publication Date Title
AR012694A1 (es) Preparado con compatibilidad in vivo incrementada y procedimiento para su produccion
KR100554811B1 (ko) 약학제형
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
ES2985732T3 (es) Productos farmacéuticos peptídicos mejorados para resistencia a la insulina
PT1030670E (pt) Utilizacao de derivados da vitamina d para potenciar a eficacia de agentes citotoxicos
BR0109272A (pt) Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
NZ527113A (en) Rapid-onset medicament for the treatment of sexual dysfunction
CY1106727T1 (el) Ινδανυλ παραγωγα για την αντιμετωπιση ασθενειων αεραγωγων
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
BR0013793A (pt) Medicamentos profiláticos e terapêuticos para doenças oftálmicas
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
CN101522692A (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药
BR0116060A (pt) Composição farmacêutica de dronedarona para administração parenteral
ES2675356T3 (es) Uso de derivados de polyamina isoprenilo en tratamiento antibiótico o antiséptico
BR0013283A (pt) Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo
Pedersen Biopharmaceutical aspects of tolfenamic acid
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
EE04264B1 (et) Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
NZ542218A (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetic acid
CN120936618A (zh) 用于共价修饰肽的阳离子脂质
ITUB20156870A1 (it) Combinazione sinergica di acido pirrolidoncarbossilico e/o suoi sali o derivati e acido ialuronico e/o suoi sali, per uso nel trattamento e/o prevenzione della secchezza e dell'irritazione delle mucose, e relative formulazioni farmaceutiche.
BR0009135A (pt) Derivado de benzamida e medicamento que ocontém
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
TR200000890T2 (tr) Topik ilacın üretilmesi için -amino levülozik asidin kullanılması

Legal Events

Date Code Title Description
FB Suspension of granting procedure